Documentdetail
ID kaart
doi:10.1007/s40618-024-02409-z...
Auteur
Galofré, J. C. Díez, J. J. Attanasio, R. Nagy, E. V. Negro, R. Papini, E. Perros, P. Žarković, M. Akarsu, E. Alevizaki, M. Ayvaz, G. Bednarczuk, T. Beleslin, B. N. Berta, E. Bodor, M. Borissova, A. M. Boyanov, M. Buffet, C. Burlacu, M. C. Dobnig, H. Fadeyev, V. Field, B. C. T. Fliers, E. Führer, D. Hakala, T. Jiskra, J. Kopp, P. Krebs, M. Kršek, M. Kužma, M. Lantz, M. Lazúrová, I. Leenhardt, L. Luchytskiy, V. Puga, F. M. McGowan, A. Metso, S. Moran, C. Morgunova, T. Niculescu, D. A. Perić, B. Planck, T. Poiana, C. Robenshtok, E. Rosselet, P. O. Ruchala, M. Riis, K. R. Shepelkevich, A. Tronko, M. Unuane, D. Vardarli, I. Visser, W. E. Vryonidou, M. Younes, Y. R. Hegedüs, L.Langue
enEditor
Springer
Categorie
Medicine & Public Health
Jaar
2024
vermelding datum
19-06-2024
Trefwoorden
obesity hypothyroidism levothyroxine survey guidelines practice 01 7% characteristics hormones thyroid p < 0 national obesity europe 0Beschrijving
Purpose The use of thyroid hormones (TH) to treat obesity is unsupported by evidence as reflected in international guidelines.
We explored views about this practice, and associations with respondent characteristics among European thyroid specialists.
Methods Specialists from 28 countries were invited to a survey via professional organisations.
The relevant question was whether “ Thyroid hormones may be indicated in biochemically euthyroid patients with obesity resistant to lifestyle interventions” .
Results Of 17,232 invitations 5695 responses were received (33% valid response rate; 65% women; 90% endocrinologists).
Of these, 290 (5.1%) stated that TH may be indicated as treatment for obesity in euthyroid patients.
This view was commoner among non-endocrinologists (8.7% vs. 4.7%, p < 0.01), private practice (6.5% vs. 4.5%, p < 0.01), and varied geographically (Eastern Europe, 7.3%; Southern Europe, 4.8%; Western Europe, 2.7%; and Northern Europe, 2.5%).
Respondents from Northern and Western Europe were less likely to use TH than those from Eastern Europe (p < 0.01).
Gross national income (GNI) correlated inversely with this view (OR 0.97, CI: 0.96–0.97; p < 0.001).
Having national guidelines on hypothyroidism correlated negatively with treating obesity with TH (OR 0.71, CI: 0.55–0.91).
Conclusions Despite the lack of evidence, and contrary to guidelines’ recommendations, about 5% of respondents stated that TH may be indicated as a treatment for obesity in euthyroid patients resistant to life-style interventions.
This opinion was associated with (i) respondent characteristics: being non-endocrinologist, working in private practice, treating a small number of hypothyroid patients annually and (ii) national characteristics: prevalence of obesity, Eastern Europe, low GNI and lack of national hypothyroidism guidelines.
Galofré, J. C.,Díez, J. J.,Attanasio, R.,Nagy, E. V.,Negro, R.,Papini, E.,Perros, P.,Žarković, M.,Akarsu, E.,Alevizaki, M.,Ayvaz, G.,Bednarczuk, T.,Beleslin, B. N.,Berta, E.,Bodor, M.,Borissova, A. M.,Boyanov, M.,Buffet, C.,Burlacu, M. C.,Dobnig, H.,Fadeyev, V.,Field, B. C. T.,Fliers, E.,Führer, D.,Hakala, T.,Jiskra, J.,Kopp, P.,Krebs, M.,Kršek, M.,Kužma, M.,Lantz, M.,Lazúrová, I.,Leenhardt, L.,Luchytskiy, V.,Puga, F. M.,McGowan, A.,Metso, S.,Moran, C.,Morgunova, T.,Niculescu, D. A.,Perić, B.,Planck, T.,Poiana, C.,Robenshtok, E.,Rosselet, P. O.,Ruchala, M.,Riis, K. R.,Shepelkevich, A.,Tronko, M.,Unuane, D.,Vardarli, I.,Visser, W. E.,Vryonidou, M.,Younes, Y. R.,Hegedüs, L., 2024, Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration, Springer
Choice Between Partial Trajectories: Disentangling Goals from Beliefs
agents models aligned based bootstrapped learning reward function model return choice choices partial
Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review
aes medications bta incidence migraine drugs disorders
